TUBERSOL
Generic: TUBERCULIN PURIFIED PROTEIN DERIVATIVE
Basic Information
Manufacturer
Sanofi Vaccines US Inc.
Product Type
HUMAN PRESCRIPTION DRUG
Route of Administration
INTRADERMAL
FDA Set ID
a4a732e9-b8ee-4e6d-8b9a-6a9d2c36bfcd
Indications & Usage
INDICATIONS AND USAGE TUBERSOL Tuberculin Purified Protein Derivative (Mantoux), is indicated to aid diagnosis of tuberculosis infection (TB) in persons at increased risk of developing active disease.
The Centers for Disease Control and Prevention (CDC) have published guidelines regarding populations that would benefit from tuberculin skin testing (TST).
Current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm.
Previous BCG vaccination is not a contraindication to tuberculin testing.
The skin-test results of BCG vaccinated persons can be used to support or exclude the diagnosis of TB infection.
However, an FDA-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with BCG.
(8)
The Centers for Disease Control and Prevention (CDC) have published guidelines regarding populations that would benefit from tuberculin skin testing (TST).
Current recommendations can be accessed at: http://www.cdc.gov/tb/publications/factsheets/testing.htm.
Previous BCG vaccination is not a contraindication to tuberculin testing.
The skin-test results of BCG vaccinated persons can be used to support or exclude the diagnosis of TB infection.
However, an FDA-approved interferon gamma release assay is preferred over tuberculin skin test for persons 5 years of age and older who were previously vaccinated with BCG.
(8)
Warnings
WARNINGS Hypersensitivity Allergic reactions may occur following the use of TUBERSOL even in persons with no prior history of hypersensitivity to the product components.
(10) Epinephrine injection (1:1,000) and other appropriate agents used for the control of immediate allergic reactions must be immediately available.
Syncope Syncope (fainting) can occur in association with administration of injectable medicines, including TUBERSOL.
Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.
(10) Epinephrine injection (1:1,000) and other appropriate agents used for the control of immediate allergic reactions must be immediately available.
Syncope Syncope (fainting) can occur in association with administration of injectable medicines, including TUBERSOL.
Procedures should be in place to avoid falling injury and to restore cerebral perfusion following syncope.
Adverse Reactions
ADVERSE REACTIONS Induration at the TUBERSOL injection site is the expected reaction for a positive skin test.
(See Interpretation of the Test .) The information pertaining to adverse events has been compiled from historical clinical studies and post-marketing experience with TUBERSOL.
General disorders and administration site conditions Injection site pain, injection site pruritus and injection site discomfort.
Injection site erythema or injection site rash (without induration) occurring within 12 hours of testing.
These reactions do not indicate TB infection.
Injection site hemorrhage and injection site hematoma up to three days after the administration of the test.
Injection site vesicles, injection site ulcer or injection site necrosis in highly sensitive persons.
Injection site scar as a result of strongly positive reactions.
Pyrexia Immune system disorders Hypersensitivity, including anaphylaxis/anaphylactic reactions, angioedema, urticaria Respiratory, thoracic, and mediastinal disorders Stridor, dyspnea Skin and subcutaneous tissue disorders Rash, generalized rash Nervous system disorders Presyncope, syncope (including syncope associated with tonic-clonic movements and other seizure-like activity) sometimes resulting in transient loss of consciousness with injury Reporting of Adverse Events To report SUSPECTED ADVERSE REACTIONS, contact the Pharmacovigilance Department, Sanofi Vaccines US Inc., Discovery Drive, Swiftwater, PA 18370 or call 1-800-822-2463 (1-800-VACCINE) or Food and Drug Administration (FDA) MEDWATCH Program at 1-800-332-1088 and www.fda.gov/medwatch.
(See Interpretation of the Test .) The information pertaining to adverse events has been compiled from historical clinical studies and post-marketing experience with TUBERSOL.
General disorders and administration site conditions Injection site pain, injection site pruritus and injection site discomfort.
Injection site erythema or injection site rash (without induration) occurring within 12 hours of testing.
These reactions do not indicate TB infection.
Injection site hemorrhage and injection site hematoma up to three days after the administration of the test.
Injection site vesicles, injection site ulcer or injection site necrosis in highly sensitive persons.
Injection site scar as a result of strongly positive reactions.
Pyrexia Immune system disorders Hypersensitivity, including anaphylaxis/anaphylactic reactions, angioedema, urticaria Respiratory, thoracic, and mediastinal disorders Stridor, dyspnea Skin and subcutaneous tissue disorders Rash, generalized rash Nervous system disorders Presyncope, syncope (including syncope associated with tonic-clonic movements and other seizure-like activity) sometimes resulting in transient loss of consciousness with injury Reporting of Adverse Events To report SUSPECTED ADVERSE REACTIONS, contact the Pharmacovigilance Department, Sanofi Vaccines US Inc., Discovery Drive, Swiftwater, PA 18370 or call 1-800-822-2463 (1-800-VACCINE) or Food and Drug Administration (FDA) MEDWATCH Program at 1-800-332-1088 and www.fda.gov/medwatch.